SP

Shanthakumarie Pather

Director Director DIN 09651104
DIN 09651104 First appointment Sep 2022 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Sep 2022
Shareholding value •••• Premium profile

About Shanthakumarie Pather

Data last updated:

Shanthakumarie Pather was a Director at Adcock Ingram Limited (2022–2025) and Director at Adcock Ingram Pharma Private Limited (2022–2025). The companies operate in Pharma.

DIN 09651104
Primary Designation Director
Industry Pharma
First Appointment 28 Sep 2022

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Adcock Ingram Limited U24232KA2007PLC042361
Director28 Sep 20222007₹464 Cr (FY 2025)Active
Adcock Ingram Pharma Private Limited U24299KA2021PTC148184
Director28 Sep 20222021₹47.27 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Adcock Ingram Limited
Adcock Ingram Pharma Private Limited
Premium access

Shareholding and investment profile for Shanthakumarie Pather

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shanthakumarie Pather

Shanthakumarie Pather was first appointed on 28 Sep 2022 as Director at Adcock Ingram Limited.

Shanthakumarie Pather held 2 earlier board appointments: Adcock Ingram Limited (Director, 28 Sep 2022 to 12 Feb 2025); Adcock Ingram Pharma Private Limited (Director, 28 Sep 2022 to 12 Feb 2025).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available